Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRIP1 mutation
i
Other names:
BRCA1 Interacting Protein C-Terminal Helicase 1, BRCA1-Associated C-Terminal Helicase 1, BRCA1/BRCA2-Associated Helicase 1, ATP-Dependent RNA Helicase BRIP1, Fanconi Anemia Group J Protein, BACH1, FANCJ, BRCA1-Binding Helicase-Like Protein BACH1, BRCA1-Interacting Protein 1, Protein FACJ, BRCA1 Interacting Protein C-terminal Helicase 1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
83990
Related biomarkers:
Expression
Mutation
Others
‹
HR positive + BRIP1 amplification (1)
HR positive + BRIP1 amplification (1)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRIP1 mutation
Prostate Cancer
BRIP1 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
BRIP1 mutation
Ovarian Cancer
BRIP1 mutation
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
olaparib
Sensitive
:
B
olaparib
Sensitive: B - Late Trials
olaparib
Sensitive
:
B
BRIP1 mutation
Prostate Cancer
BRIP1 mutation
Prostate Cancer
rucaparib
Sensitive: C2 – Inclusion Criteria
rucaparib
Sensitive
:
C2
rucaparib
Sensitive: C2 – Inclusion Criteria
rucaparib
Sensitive
:
C2
BRIP1 mutation
Urothelial Cancer
BRIP1 mutation
Urothelial Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
olaparib
Sensitive
:
C2
olaparib
Sensitive: C2 – Inclusion Criteria
olaparib
Sensitive
:
C2
BRIP1 mutation
HER2 Negative Breast Cancer
BRIP1 mutation
HER2 Negative Breast Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
durvalumab
Sensitive
:
C2
durvalumab
Sensitive: C2 – Inclusion Criteria
durvalumab
Sensitive
:
C2
BRIP1 mutation
Pancreatic Cancer
BRIP1 mutation
Pancreatic Cancer
nivolumab + ABT-888
Sensitive: C3 – Early Trials
nivolumab + ABT-888
Sensitive
:
C3
nivolumab + ABT-888
Sensitive: C3 – Early Trials
nivolumab + ABT-888
Sensitive
:
C3
BRIP1 mutation
Colon Cancer
BRIP1 mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.